Background
Methods
Study design and population
Definitions
Microbiology
Statistical analysis
Results
Increased rates of CRKP-BSIs, especially among ICU patients
Risk factors associated with the development of CRKP-BSIs
Variable | Total (n = 114) n(%) | CRKP (n = 33) n(%) | CSKP (n = 81) n(%) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|---|---|
OR(95% CI) |
p-value | OR(95% CI) |
p-value | ||||
General variables | |||||||
Male sex | 74(64.9) | 22(66.7) | 52(64.2) | 1.12(0.5-2.6) | 0.802 | ||
Age,years, mean ± SD | 56.37 ± 16.36 | 51.70 ± 16.26 | 58.27 ± 16.11 | NA | 0.051 | ||
Poly-microbial BSI | 11(9.6) | 6(18.2) | 5(6.2) | 3.38 (1.0–12.0) | 0.076 | ||
Nosocomial infection | 98(86.0) | 33(100) | 65(80.2) | NA | 0.005 | - | - |
ICU acquired infection | 26(22.8) | 14(42.4) | 12(14.8) | 4.24(1.7–10.7) | 0.001 | 5.82(2.0–17.2) | 0.002 |
Comorbidities | |||||||
Diabetes mellitus | 30(26.3) | 3(9.1) | 27(33.3) | 0.20(0.1–0.7) | 0.008 | ||
Chronic renal failure | 8(7.0) | 3(9.1) | 5(6.2) | 1.52(0.3–6.8) | 0.689 | ||
Chronic liver disease | 20(17.5) | 5(15.2) | 15(18.5) | 0.79(0.3–2.4) | 0.668 | ||
Liver cirrhosis | 11(9.6) | 2(6.1) | 9(11.1) | 0.52(0.1–2.5) | 0.506 | ||
Biliary tract disease | 35(30.7) | 9(27.3) | 26(32.1) | 0.79(0.3–1.9) | 0.612 | ||
Congestive heart failure | 9(7.9) | 4(12.1) | 5(6.2) | 2.10(0.5–8.4) | 0.280 | ||
Chronic obstructive pulmonary disease | 3(2.6) | 1(3.0) | 2(2.5) | 1.23(0.1–14.1) | 1 | ||
Malignancy | 59(51.8) | 12(36.4) | 47(58.0) | 0.41(0.2–1.0) | 0.036 | ||
Immunosuppression | 26(22.8) | 10(30.3) | 16(19.8) | 1.77(0.7–4.4) | 0.223 | ||
CCI,median (IQR) | 3(2–6) | 3(0–4) | 4(2–6) | NA | 0.005 | - | - |
Probable source of infection | |||||||
Lung | 16(14.0) | 5(15.2) | 11(13.6) | 1.14(0.4–3.6) | 0.776 | ||
Urinary | 1(0.9) | 0(0) | 1(0.9) | NA | 1 | ||
Intra-abdominal | 48(42.1) | 12(36.4) | 36(44.4) | 0.71(0.3–1.6) | 0.428 | ||
Liver abscess | 6(5.3) | 1(3.0) | 5(6.2) | 0.48(0.1–4.2) | 0.671 | ||
Skin and soft tissue | 12(10.5) | 10(30.3) | 2(2.5) | 17.17(3.5–84.0) | <0.001 | 26.63(4.8–146.8) | <0.001 |
Catheter | 10(8.8) | 5(15.2) | 5(6.2) | 2.71(0.7–10.1) | 0.150 | ||
Primary | 27(23.7) | 5(15.2) | 22(27.2) | 0.48(0.2–1.4) | 0.171 | ||
Hospital events prior to onset of BSI | |||||||
Exposure to antimicrobial therapy a
| 74(64.9) | 30(90.9) | 44(54.3) | 8.41(2.4–29.8) | <0.001 | 4.04(1.0–16.5) | 0.052 |
Surgery a
| 62(54.4) | 21(63.6) | 41(50.6) | 1.71(0.7–3.9) | 0.206 | ||
Events on the onset of BSI | |||||||
SOFA score,median (IQR) | 3(1–6) | 4(1–7) | 3(1–5) | NA | 0.098 | ||
PBS,median (IQR) | 1(1-2.25) | 2(1–5) | 1(0–2) | NA | <0.001 | - | - |
Comparison of antimicrobial therapies and treatment outcomes between CRKP-BSI and CSKP-BSI patients
Treatment and outcomes | Total (n = 114) | CRKP (n = 33) | CSKP (n = 81) |
p-value |
---|---|---|---|---|
Appropriate empirical antimicrobial therapy | 78(68.4) | 9(27.3) | 69(85.2) | <0.001 |
LOS after BSI onset,Days, median (IQR) | 18.5(9–31) | 24(9.5–51) | 15(8.5–28) | 0.066 |
Total LOS,days, median (IQR) | 31.5(19.75–62.75) | 50(28–83) | 24(16.5–51) | 0.001 |
Mortality rate | ||||
Crude 28-day mortality n(%) | 26(22.8) | 11(33.3) | 15(18.5) | 0.087 |
Crude in-hospital mortality n(%) | 30(26.3) | 14(42.4) | 16(19.8) | 0.013 |
Attributable 28-day mortality n(%) | 24(21.1) | 11(33.3) | 13(16.0) | 0.04 |
Attributable in-hospital mortality n(%) | 28(24.6) | 14(42.4) | 14(24.6) | 0.005 |
Identification of clinical and microbiological characteristics associated with crude 28-day mortality
Variable | Total (n = 114) n(%) | Death (n = 26) n(%) | Survivors (n = 88) n(%) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|---|---|
OR(95% CI) |
p-value | OR(95% CI) |
p-value | ||||
General variables | |||||||
Male sex | 74(64.9) | 20(76.9) | 54(61.4) | 2.10(0.8–5.8) | 0.144 | ||
Age,years, mean ± SD | 56.37 ± 16.36 | 55.54 ± 16.10 | 56.61 ± 16.52 | NA | 0.770 | ||
Poly-microbial BSI | 11(9.6) | 3(11.5) | 8(9.1) | 1.30(0.3–5.3) | 0.711 | ||
Nosocomial infection | 98(86.0) | 23(88.5) | 75(85.2) | 1.33(0.3–5.1) | 1 | ||
ICU acquired infection | 26(22.8) | 10(38.5) | 16(18.2) | 2.81(1.1–7.3) | 0.03 | - | - |
Comorbidities | |||||||
Diabetes mellitus | 30(26.3) | 4(15.4) | 26(29.5) | 0.43(0.1–1.4) | 0.150 | ||
Chronic renal failure | 8(7.0) | 1(3.8) | 7(8.0) | 0.463(0.05–3.9) | 0.680 | ||
Chronic liver disease | 20(17.5) | 9(34.6) | 11(12.5) | 3.71(1.3–10.3) | 0.017 | ||
Liver cirrhosis | 11(9.6) | 5(19.2) | 6(6.8) | 3.25(0.9–11.7) | 0.122 | ||
Biliary tract disease | 35(30.7) | 8(30.8) | 27(30.7) | 1.00(0.4–2.6) | 1 | ||
Congestive heart failure | 9(7.9) | 5(19.2) | 4(4.5) | 5.00(1.2–20.2) | 0.028 | ||
Chronic obstructive pulmonary disease | 3(2.6) | 0(0) | 3(3.4) | NA | 1 | ||
Malignancy | 59(51.8) | 11(42.3) | 48(54.5) | 0.61(0.3–1.5) | 0.273 | ||
Immunosuppression | 26(22.8) | 6(23.1) | 20(22.7) | 1.02(0.4–2.9) | 0.97 | ||
Charlson comorbidity index, median (IQR) | 3(2–6) | 3(2–6.75) | 3(1.25–6) | NA | 0.576 | ||
Probable source of infection | |||||||
Lung | 16(14.0) | 9(34.6) | 7(8.0) | 6.13(2.0–18.7) | 0.002 | 4.23(1.0–17.3) | 0.045 |
Intra-abdominal | 48(42.1) | 9(34.6) | 39(44.3) | 0.67(0.3–1.7) | 0.379 | ||
Skin and soft tissue | 12(10.5) | 4(15.4) | 8(9.1) | 1.82(0.5–6.6) | 0.465 | ||
Catheter-related | 10(8.8) | 2(7.7) | 8(9.1) | 0.83(0.2–4.2) | 1 | ||
Hospital events prior to onset of BSI | |||||||
Exposure to antimicrobial therapy a
| 74(64.9) | 20(76.9) | 54(61.4) | 2.10(0.8–5.8) | 0.144 | ||
Surgery a
| 62(54.4) | 15(57.7) | 47(53.4) | 1.19(0.5–2.9) | 0.700 | ||
Events on the onset of BSI | |||||||
Acute kidney injury | 16(14.0) | 12(46.2) | 4(4.5) | 18.00(5.1–63.8) | <0.001 | ||
Use of renal replacement therapy | 8(7.0) | 5(19.2) | 3(3.4) | 6.75(1.5–30.5) | 0.015 | ||
Septic shock | 28(24.6) | 16(61.5) | 12(13.6) | 10.13(3.7–27.5) | <0.001 | ||
Use of mechanical ventilation | 24(21.1) | 15(57.7) | 9(10.2) | 11.97(4.2–33.9) | <0.001 | ||
Removal of the infectious source | 33(28.9) | 6(23.1) | 27(30.7) | 0.68(0.2–1.9) | 0.453 | ||
SOFA score, median (IQR) | 3(1–6) | 9(4–13.5) | 2(1–4) | NA | <0.001 | 1.40(1.2–1.6) | <0.001 |
Pitt bacteraemia score, median (IQR) | 1(1–2.25) | 5(2–7) | 1(1–2) | NA | <0.001 | - | - |
CRKP | 33(28.9) | 11(42.3) | 22(25.0) | 2.20(0.9–5.5) | 0.087 | ||
Appropriate empirical therapy | 78(68.4) | 14(53.8) | 64(72.7) | 0.44(0.2–1.1) | 0.069 |